Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Endostatin and Paclitaxel–Carboplatin Chemotherapy? A Retrospective Study  by Chu, Tian-Qing et al.
1781Journal of Thoracic Oncology  •  Volume 7, Number 12, December 2012
Introduction: Early prediction of the efficacy of a combination of 
an antiangiogenic drug with cytotoxic chemotherapy is a significant 
challenge. In that regard, circulating endothelial cells (CECs) and 
cytokeratins (CKs) seem to reflect their roles in both tumor angio-
genesis and tumor cell death.
Methods: Patients with advanced, previously untreated non–small-
cell lung cancer were randomly assigned to an endostatin treatment 
group (paclitaxel + carboplatin + endostatin) and a control group 
(paclitaxel + carboplatin + placebo). A total of 122 patients were 
evaluated, of whom 107 had measurements of blood CECs, CK8, 
caspase-cleaved CK18 (ccCK18), and uncleaved CK18 (CK18) 
before and at weeks 3 and 6 of treatment, respectively.
Results: Higher baseline CECs in patients with a tumor response 
(partial remission + stable disease, p = 0.002 for the entire group; 
p = 0.000 for the treatment group) were observed. The number of 
CECs decreased significantly after endostatin treatment (p = 0.000), 
whereas CK levels increased. Increased levels of ccCK18 and CK18, 
but not CK8, reached significance (p = 0.001 and p = 0.048, respec-
tively) when compared with the baseline. Tumor response showed a 
strong correlation with reduction of CECs (p = 0.000) and increase 
of ccCK18 (p = 0.040) after endostatin therapy. Cutoff values of 
changes of CECs and ccCK18 for prediction of survival were 0.58/μl 
and 19.6 ng/ml, respectively. Reduction of CECs and increase 
of ccCK18 significantly correlated with longer median survival 
(p = 0.013 and p = 0.016 for progression-free survival; p = 0.009 and 
p = 0.012 for overall survival, respectively).
Conclusions: CECs and CKs could be biomarkers for selecting 
patients with non–small-cell lung cancer who will benefit from treat-
ment with endostatin in combination with paclitaxel plus carboplatin.
Key Words: Circulating endothelial cells, Cytokeratins, Endostatin, 
Biomarker, Non–small-cell lung cancer.
(J Thorac Oncol. 2012;7: 1781–1789)
Non–small-cell lung cancer (NSCLC) accounts for the most cancer deaths worldwide, along with a 5-year survival of 
only 5% to 15%.1 Chemotherapy remains an important modality 
for treatment of this tumor, in particular, for those with advanced 
disease. However, response rates to chemotherapy are only 
approximately 30% and have only slightly improved results in 
recent years, making its treatment a challenge.2 Antiangiogenic 
drugs, usually in combination with chemotherapy, are sometimes 
used. Increasing clinical evidence indicates that such drugs can 
reduce tumor angiogenesis and inhibit growth of solid tumors.3–5
Endostatin, a peptide identified in 1996, specifically 
acts against tumor-related neovascular endothelial cells (ECs), 
inducing cancer cell apoptosis.6 Clinical trials have positively 
evaluated its application in NSCLC.7 A previously multi-
center, randomized, phase II, double-blind, placebo-controlled 
study in China evaluated it as first-line therapy for advanced 
NSCLC and found that paclitaxel–carboplatin with endostatin 
significantly improved the objective response rate, although 
neither longer progression-free survival (PFS) nor better over-
all survival (OS) was achieved.8
Paclitaxel, an active agent in NSCLC, not only induces 
tumor cell apoptosis and necrosis but also has antiangiogenic 
activity, thereby reducing the number of circulating endo-
thelial cells (CECs).9 However, it has been difficult to better 
assess and predict the efficacy of combined antiangiogenesis 
and paclitaxel-based chemotherapy.10 Thus, biomarkers may 
be useful.
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Neovascularization in tumor vessels is generated by 
mature ECs. Thus, the role of CECs and circulating progenitor 
(CEP) cells in cancer growth and their measurement as 
biomarkers in antiangiogenic cancer therapy is important. 
It has been demonstrated that CEC levels are increased in 
various cancers at diagnosis and subsequently reduced, even 
close to normal, in patients achieving complete remission.11 
In patients with metastatic breast cancer, for example, treated 
with low-dose metronomic chemotherapy for 2 months with 
continuous therapy, CEC levels were a predictor of disease-
free survival (DFS) and OS after a 2-year follow-up.12 Previous 
investigations showed that levels of CECs and CEPs were 
strongly elevated in patients with advanced NSCLC. CEC 
count at baseline was significantly higher in patients with 
NSCLC than in healthy volunteers. Pretreatment CEC values 
were significantly higher in patients experiencing a clinical 
benefit (partial response, stable disease) than in patients with 
progressive disease. A statistically significant decrease in 
CECs on day 22 was observed only in patients with a partial 
response.13 Significantly increased CEP levels were noted 
before the first and second cycles of chemotherapy. Although 
there was a decrease of CEPs noted on the eighth day after 
treatment, this did not predict an improvement in PFS.14
Serum levels of various cytokeratins (CKs) have been 
proposed as biomarkers of chemotherapy-induced tumor cell 
death.15,16 Reported NSCLC CKs have mainly been CK7, 
CK8, CK18, and CK19.17 Increased CK8 and CK18 have also 
been associated with tumor progression and decreased sur-
vival.18,19 The latter two CKs are coexpressed and constitute 
the primary keratin pair on one-layered epithelial cells.20 They 
are released into the circulation, remaining in a relatively sta-
ble state in either their intact or caspase-cleaved forms during 
necrotic and apoptotic cell death. Extracellular release of CK8 
in NSCLC caused by apoptosis is full length. Measurement of 
molecular subtypes of CK18 can identify epithelial-derived 
cell death. For example, caspase-cleaved CK18 fragments 
(ccCK18), a result of apoptosis, and uncleaved CK18 (CK18) 
are released from necrotic cells. Thus, CK18s are potentially 
both quantitative and qualitative biomarkers for cell death.21 
In fact, plasma CK18 levels have been used as markers of 
response to chemotherapy in patients with gastrointestinal 
adenocarcinomas.22
To investigate whether there are biomarkers for select-
ing patients with NSCLC who might benefit from continued 
endostatin in combination with paclitaxel plus carboplatin,8 
we evaluated serum CK8, ccCK18, CK18, and CECs in 
patients with advanced NSCLC receiving one of two random-
ized treatments. Serum levels of CKs and CECs at baseline, 
week 3, and week 6 after therapy were measured to assess 
their predictive or monitoring for tumor response and possible 
correlation with survival.
MATERIALS AND METHODS
Patient Selection
This was a randomized, double-blind, placebo-con-
trolled, multicenter phase II trial. Inclusion criteria, study 
design, and informed consent and ethics were described 
previously
.
8 One hundred and twenty-six patients with previ-
ously untreated and advanced NSCLC were enrolled and ran-
domly assigned to the treatment group (n = 63) and the control 
group (n = 63). One patient in each group withdrew before 
treatment, and one patient in each group was excluded because 
of paclitaxel allergy. Thus, by intent to treat, 122 patients were 
included in the efficacy analysis, 61 in each group.8
Therapy Strategy
Patients enrolled were randomly divided into end-
ostatin group (paclitaxel plus carboplatin plus endostatin) 
and control group (paclitaxel plus carboplatin plus placebo). 
Recombinant human endostatin was provided by Shandong 
Simcere-Medgenn Bio-Pharmaceuticals (National Medicine 
Permit No. S20050088).8
Treatment schemes were described previously.8 
Paclitaxel (175 mg/m2, d1) and carboplatin (area under the 
curve [AUC] = 5, d1) were administrated on the first day of 
each cycle with endostatin or placebo by intravenous infusion 
on days 8 to 21, with 21 days per cycle. Treatment was con-
tinued until progressive disease (PD) or unacceptable toxicity 
to a maximum of four cycles. Tumor size was determined by 
computed tomography scans at baseline and after each cycle 
of chemotherapy. Patient response was evaluated according 
to Response Evaluation Criteria in Solid Tumors criteria: 
complete response (CR), partial remission (PR), stable dis-
ease (SD), and PD.23 Toxicity was assessed once a week and 
recorded according to World Health Organization toxicity 
criteria.24
Blood Collection and Evaluation 
of CECs and CKs
Five patients in the treatment group and four in the con-
trol group declined to provide blood samples. Blood samples 
before or after treatment from two patients in the endostatin 
group and four in the control group could not be successfully 
obtained. Therefore, a total of 107 patients were included in 
the final analysis, 54 in the endostatin, and 53 in the control 
groups. Peripheral blood was taken from patients on three 
occasions: at baseline and at weeks 3 and 6, for CK and CEC 
determination.
Blood was collected in ethylenediaminetetraacetic acid 
tubes, with circulating CECs being measured using a full 
blood-flow cytometric method.12 CECs were defined: nega-
tive for hematopoietic marker CD45, positive for endothelial 
marker P1H12, negative for progenitor marker CD133.12 A 
volume of 1.5 ml full blood was used for flow cytometry, and 
appropriate IgG isotypes were used as control. Cell suspen-
sions were evaluated after red cell lysis with lysing solution 
(Beckman Coulter). Antibodies were from Becton Dickinson 
(USA), with anti-CD45 used to exclude hematopoietic cells 
and anti-CD133 to exclude progenitor cells P1H12 (CD146, 
an EC marker). Using FL-3/SSC gating strategy, acquisi-
tion was performed by flow cytometry (Becton Dickinson, 
FACSCalibur) equipped with a 488-nm argon-ion laser. 
Software-Cellqust (Becton Dickinson) was used to analyze 
sample data (Fig. 1).
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Sera were collected at baseline and at weeks 3 and 6. 
Samples were stored at −80°C until analysis. Serum CK8, 
ccCK18, and CK18 levels were measured with enzyme-linked 
immunosorbent assay kit (R&D, China). Concentration of CK 
antigens was expressed as ng/ml.
Statistical Analysis
Statistical analysis was performed using SPSS13.0 ver-
sion. Nonparametric statistics were used because of nonnormal 
distribution of the study parameters. Mann–Whitney U test was 
used to test for correlations of biomarkers and tumor response 
between the two groups. Wilcoxon matched-pair signed ranks test 
was used to examine two related samples represented by CECs 
and CK antigens before and after chemotherapy. Pearson’s cor-
relation test was used when determining an association between 
changes of CECs and CK antigens. To evaluate values of serum 
level of CK antigens and CECs in the prediction of patient sur-
vival, receiver operating characteristic (ROC) curve analysis was 
performed. Correlations with PFS and OS were determined with 
the Kaplan–Meier method and log-rank statistic. All tests were 
used to assess the prognostic significance of parameters taken in 
association, using a two-sided level of 0.05.
RESULTS
Patient Characteristics
Patient characteristics are shown in Table 1. No patients 
died during the course of the 6 weeks. All tested individuals 
had blood samples taken at the various sampling stages, except 
one patient who showed PD at week 3. His blood samples were 
taken at baseline and week 3 and included in the analysis.
Serum CK8, ccCK18, CK18, and 
CECs before Treatment
Serum baseline CK8, ccCK18, and CK18 levels dem-
onstrated median values for CK8 of 30.28 ng/ml (range, 4.43–
120.43 ng/ml), ccCK18 of 64.60 ng/ml (range, 7.02–170.15 ng/
ml), and CK18 of 417.48 ng/ml (range, 104.47–2164.62 ng/ml). 
Pretreatment CECs ranged from 0.15 to 2.50/μl (median 1.07/μl).
There was no significant association of serum CK8, 
ccCK18, CK18, or CEC levels at baseline with patient 
demographic factors, including age, sex, histology, staging, 
smoking history, or Eastern Cooperative Oncology Group sta-
tus in either the entire group or the two treatment groups (data 
not shown).
No association between tumor response and the various 
CK levels at baseline was observed. Median CECs at base-
line for the entire group, however, were statistically higher 
(1.12/μl versus 0.33/μl) in patients who subsequently devel-
oped PR/SD (n = 90) than in the patients with PD (n = 17, 
p = 0.002). This was because of the endostatin group, where 
there was a significant relationship between pretreatment CEC 
levels and tumor response (n = 47 for PR/SD, n = 7 for PD, 
p = 0.000), whereas in the control group, a significant relation-
ship between tumor response and baseline CEC levels was not 
noted. (n = 45 for PR/SD, n = 8 for PD, p = 0.066).
Changes of Serum CK8, ccCK18, CK18, 
and CECs during Treatment
In the control group, CK levels after chemotherapy were 
stable or lower than at baseline, whereas in the endostatin group, 
CK levels gradually increased with therapy. Of the three CKs 
subtypes, ccCK18 and CK18 increases at week 6 reached sig-
nificance (p = 0.001 and p = 0.048, respectively). Furthermore, 
when comparing CK levels between endostatin and control 
groups, CK levels at two different time points, 3 and 6 weeks 
after treatment, were significantly higher in the endostatin 
group (week 3: p = 0.003 for CK8; p = 0.008 for ccCK18; p = 
0.356 for CK18 [not significant]. Week 6: p = 0.006 for CK8; 
p  = 0.007 for ccCK18; p = 0.028 for CK18 [see Fig. 2A]).
The CEC counts of endostatin group decreased signifi-
cantly at both 3 weeks (p = 0.015) and 6 weeks (p = 0.000). 
Similarly, when also compared with control group, CECs in 
the endostatin group showed a significant decrease at week 6 
(p = 0.054 at week 3, p = 0.000 at week 6, Fig. 2B).
Correlation of Change of Serum CK8, ccCK18, 
CK18 and CEC Levels with Tumor Response
Objective tumor response data were available from all 
107 patients, including 22 with PR, 25 with SD, and 7 with 
PD in the endostatin group (Table 1). ccCK18 increase from 
baseline to week 6 was significant in treatment patients who 
achieved PR/SD when compared with PD (p = 0.040, Fig. 3A). 
However, in contrast, no statistical response correlations were 
FIGURE 1.  Representative CEC 
enumeration by flow cytometry. A, Panels 
showing the gate used to exclude CD45− 
positive cells. B, Panels showing the gate 
used to count CECs (defined as CD45− 
CD146+ CD133−). CEC, circulating 
endothelial cell.
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observed in CK8, CK18, or the control group after two cycles 
of therapy. Tumor response in the endostatin group, however, 
showed a strong correlation with reduced CEC at week 6 (p = 
0.000, Fig. 3B).
Association between Change of ccCK18, 
CK18, and CECs and Patient Survival
In our previous report,8 paclitaxel–carboplatin plus 
endostatin showed an improvement in overall response rate 
(p = 0.078) but failed to reach a survival benefit. In the cur-
rent study, however, whether biomarker changes could predict 
patient survival was addressed.
The relationship between increased ccCK18 and 
patient survival (PFS and OS) was analyzed by ROC in the 
endostatin group. The optimal cutoff value for prediction 
of survival was 19.6 ng/ml, where AUC = 0.704 (95% CI = 
0.559–0.849). Sensitivity and specificity of the ccCK18 end-
ostatin-induced increase were calculated using ROC analysis 
for survival. The result was 70% for sensitivity and 61% for 
specificity (Fig. 4A).
Median PFS and OS for the patients treated with end-
ostatin were 6.5 and 17.6 months, respectively. The rela-
tionship between ccCK18 and survival was analyzed by the 
Kaplan–Meier analysis. With a cutoff of 19.6 ng/ml, patients 
with a lesser ccCK18 increase (n = 26) had a median sur-
vival (MS) of 5.5 months for PFS and 14.9 months for OS. 
However, those with a greater increase (n = 27) survived for 
medians of 9.1 and 22.6 months for PFS and OS, respectively. 
This translated into a significant survival benefit for those with 
the higher ccCK18 increase (p = 0.016 for PFS; p = 0.012 for 
OS) (Fig. 4B and C).
Similarly, the relationship between decreased CEC and 
patient survival (PFS and OS) was analyzed. ROC analysis 
revealed the optimal cutoff value for prediction of survival 
as 0.58/μl, where AUC = 0.759 (95% CI = 0.629–0.889, 
Fig. 5A). Sensitivity and specificity of the endostatin-induced 
CEC decrease were calculated using ROC analysis for sur-
vival. They were 60% and 88%, respectively. With a cutoff 
value of 0.58/μl, patients with a less CEC reduction (n = 34) 
had a 5.0-month PFS and 10.6-month median OS, whereas 
those with a greater CEC reduction (n = 19) had a 9.8-month 
PFS and 23.9-month median OS. This demonstrated that MS 
with the greater reduction of CECs after endostatin treat-
ment was significantly longer (p = 0.013 for PFS, p = 0.009 
for OS) (Fig. 5B and C). However, in the control group, 
changes in CEC and CK18 levels failed to predict PFS or OS 
(data not shown).
Correlation of Serum ccCK18 and CK18  
Levels and CECs during Therapy for the  
Entire Group
Correlation of dynamic changes of CKs and CECs dur-
ing therapy in the 107 patients was evaluated. In the entire 
group, strong correlation was observed between the increase 
of ccCK18 levels and the reduction of CECs (r = −0.203, 
p = 0.048; Fig. 6A). The increase of ccCK18 and CK18 
TABLE 1. Clinical Characteristics of the Patients with NSCLC
Characteristics Paclitaxel/Carboplatin + Endostatin(n = 54) Paclitaxel/Carboplatin + Placebo(n = 53)
Age, range(yr) 57.35 (39–79) 57.4 (29–75)
Sex, n (%)
Male 37 (68.5) 41 (77.4)
Female 17 (31.5) 12 (22.6)
Smoking
Yes 27 (50.0) 29 (54.7)
No 27 (50.0) 24 (45.3)
Baseline ECOG performance status, n (%)
0 7 (13.0) 6 (11.3)
1 47 (87.0) 47 (88.7)
Pathological subtype, n (%)
Adenocarcinoma 37 (68.5) 41 (77.4)
Squamous-cell carcinoma 17 (31.5) 12 (22.6)
Clinical stage, n (%)
IIIb 23 (42.6) 20 (37.7)
IV 31 (57.4) 33 (62.3)
Chemotherapy outcome, n (%)
PR 22 (40.7) 12 (22.6)
SD 25 (46.3) 33 (62.3)
PD 7 (13.0) 8 (15.1)
Median PFS, range (m) 6.5 (0.7–31.6) 6.0 (1.0–24.6)
Median OS, range (m) 17.6 (4.5–31.8) 18.7 (2.3–33.4)
NSCLC, non–small-cell lung cancer; PR, partial remission; SD, stable disease; PD, progressive disease; ECOG, Eastern Cooperative Oncology Group; PFS, progression-free 
survival time;OS, overall survival time.
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synchronously occurred during therapy and the correlation 
between them was significant (r = 0.260, p = 0.010; Fig. 6B).
DISCUSSION
With increasing use of antiangiogenic therapy for can-
cer, conventional measurement tools or biomarkers might not 
be sufficient to evaluate clinical efficacy of these targeted 
drugs. New surrogates for pharmacodynamic markers reflect-
ing drug activity are much needed.
In this study, we measured and compared serum levels 
of CECs, CK8, and two different subtypes of CK18 (caspase-
cleaved CK18 and uncleaved CK18) in patients with advanced 
NSCLC treated with paclitaxel plus carboplatin combined 
with or without the antiangiogenic agent, endostatin. The 
specificity of changes in serum CECs and CK levels with end-
ostatin treatment and their relationship to tumor response and 
survival was also evaluated.
The data showed that baseline CECs seemed to predict 
treatment outcome in the 107 patients with advanced NSCLC. 
Patients presenting with lower CEC levels tended to have PD 
in both treatment arms. One can only speculate about the basis 
of this finding. Baseline CEC levels might then be an indica-
tion for the general use, or not, of antiangiogenic agents. It 
was also found that the level of CECs decreased significantly 
after 6 weeks in the endostatin-treated group compared with 
the control. Reduction of CECs during endostatin therapy 
FIGURE 2.  Dynamic changes of serum CK and CEC counts before and during treatment course at weeks 3 and 6. A, No sig-
nificant difference observed in CKs between two groups. After endostatin therapy, serum CK levels showed gradual increase. Of 
the three CKs, increased ccCK18 and CK18 levels at week 6 reached significance in endostatin group (p = 0.001 and p = 0.048, 
respectively). Furthermore, when comparing serum CK changes between therapy courses of endostatin group and control 
groups, CK levels at weeks 3 and 6 were significantly increased (p = 0.003 for CK8, p = 0.008 for ccCK18, p = 0.356 for CK18 at 
week 3; p = 0.006 for CK8, p = 0.007 for ccCK18, p = 0.028 for CK18 at week 6, respectively). B, CECs decreased significantly 
after 6 weeks of endostatin therapy when compared with baseline (p = 0.000). Similarly, when compared with control group, 
CECs in the endostatin group showed significant decrease at week 6 (p = 0.000). CEC, circulating endothelial cell; CKs, cyto-
keratins; ccCK18, caspase-cleaved cytokeratins.
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FIGURE 3.  Correlation of changes of 
serum ccCK18 and CECs with tumor 
response. A, Increase of caspase-
cleaved CK18 level at week 6 was 
significant in patients treated with 
endostatin achieving PR/SD when 
compared with PD (p = 0.04). B, 
Strong correlation of tumor response 
with CEC reduction at 6 weeks 
treatment with endostatin (p = 0.000). 
CEC, circulating endothelial cell; CKs, 
cytokeratins; ccCK18, caspase-cleaved 
cytokeratins; PR, partial remission; SD, 
stable disease; PD, progressive disease.
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might thus be a predictor of continued therapy, outcome, and 
survival. Moreover, it was found that a greater CEC reduc-
tion indicated that patients treated with endostatin were 
more likely to have PR/SD (p = 0.000). Specifically, analy-
sis revealed that patients with CECs reduction of more than 
0.58/μl during endostatin therapy had better PFS and OS (9.8 
versus 5 months, p = 0.013 for PFS; 23.9 versus 10.6 months, 
p = 0.009 for OS).
It has been unclear whether serum biomarkers can assist 
in determining treatment response. The question remains 
whether the parameters of drug-induced cell death can show 
a significant correlation with tumor response. In patients 
with locally advanced breast cancer, a significant correlation 
was seen between an increase in apoptosis index and clinical 
response to neoadjuvant chemotherapy.25 However, in one lung 
cancer study, no association was found between postchemo-
therapy ccCK18 levels and survival.18 The current study failed 
to prove outcome predictability of baseline CKs. However, it 
was demonstrated that the degree of increase of ccCK18 at 
week 6 of endostatin therapy seemed to reflect a drug-induced 
tumor response (p = 0.040). Although CK8, ccCK18, and 
CK18 levels increased significantly after 6 weeks treatment 
with endostatin compared with controls, only ccCK18 in the 
treatment group had a statistically significant increase in PR/
SD (p = 0.04). Moreover, patients with levels of ccCK18 that 
increased more than19.6 ng/ml with endostatin therapy at 6 
weeks showed significantly better PFS and OS (9.1 versus 5.5 
months, p = 0.016 for PFS; 22.6 versus 14.9 months, p = 0.012 
for OS). This suggests that the increased ccCK18 in patients 
with a clinical benefit was caused by an increase in endostatin-
induced apoptotic-derived ccCk18.
Our study showed that CEC reduction during therapy 
significantly correlated with an increase in ccCK18 (r =−0.203, 
p = 0.048). In addition, the increases of ccCK18 and CK18 
were synchronous during therapy, with their correlation being 
significant for the entire group (r = 0.260, p = 0.01). Finally, 
this seems to demonstrate that chemotherapy, both with and 
without endostatin, leads to ccCK18 and CK18 release from 
tumor cell death, and that CECs are reduced accordingly.
Serum CK8 and CK18 assays have also recently been 
found to be clinically useful biomarkers because of features 
such as epithelial specificity and their abundant expression in 
epithelial cells and complexes.15 Caspase-cleaved CK18 can 
be easily identified by use of monoclonal antibody M30, which 
recognizes a neoepitope of CK18 generated during apoptosis.26 
Therefore, measurement of such CKs may also facilitate both 
prediction and prognosis in patients being treated for cancer. 
With regard to the use of CK18 as a tumor response biomarker, 
there is a concern as to whether circulating CK18 is a real 
reflection of its release from tumor cells, instead of other 
cells. Observations from previous studies, however, suggest 
that CKs are, in fact, derived from tumor cells. For example, 
FIGURE 4.  Association between 
increase of ccCK18 and patient 
survival in the endostatin group. A, 
Best cutoff value of ccCK18 increase 
for prediction of survival was 19.6 ng/
ml where AUC = 0.704 (95% CI 
= 0.559–0.849). Sensitivity and 
specificity of ccCK18 increase after 
endostatin therapy calculated using 
ROC analysis for survival were 70% 
and 61%, respectively. B and C, 
When cutoff value of 19.6 ng/ml was 
used, patients whose ccCK18 levels 
increased less (n = 26) presented 
shorter median survival (5.5 months 
for PFS, 14.90 months for OS). Those 
with significantly increased ccCK18 
antigen levels (n = 28) survived 9.1 
months for PFS and 22.6 months for 
OS. Median survival of patients with 
increased ccCK18 after endostatin 
treatment was statistically longer 
than those with less increase ccCK18 
(p = 0.016 for PFS, p = 0.012 for OS). 
ccCK18, caspase-cleaved cytokera-
tins; ROC, receiver operating charac-
teristic; PFS, progression-free survival; 
OS, overall survival; AUC, area under 
the curve.
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CK18 levels generally decreased after surgical removal of 
tumors.27 Higher serum CK18 levels were detected in local 
tumor veins compared with peripheral blood in the same 
patients with endometrial carcinoma.15 A strong association 
between the amplitude of docetaxel-induced increases in 
ccCK18/CK18 and tumor load in patients with prostate cancer 
suggested that CK18 originated from the tumor de novo.28 An 
association between CK18 markers and number of circulating 
tumor cells in patients treated with platinum-based therapy 
has been demonstrated.29 It is, therefore, likely that increased 
serum CK18 levels in patients are due to release by the 
tumors. Moreover, the relationship between CK18 increases 
and tumor response observed in various studies also indicates 
that CK18 is derived from tumor cells.22,30,31
However, it has also been noted that circulating CK18 
increases might be derived from drug overexposure and thus 
could represent toxicity. Hepatocytes express CK18, and liver 
toxicity induced by cancer therapeutics may release CK18. 
Thus, it may be advisable to determine whether an agent can 
induce liver toxicity before clinical studies if CK18 markers 
are being used to monitor treatment response. Alternatively, 
it is beneficial to measure liver enzymes, such as aspartate 
aminotransferase (AST)/alanine aminotransferase, in parallel 
with CK18 levels, to observe liver toxicity in clinical studies.
In this study, liver toxicity was not a common side 
effect induced by endostatin. AST/alanine aminotransferase 
was measured at baseline and at weeks 3 and 6 in parallel 
with CK18 levels. No grade 3 or grade 4 liver toxicity was 
observed. Only two patients, one in the endostatin group, the 
other in the control group, had a slight increase of AST (grade 
1) after the first cycle of treatment. Using compound glycyr-
rhizin, enzyme levels in the two were close to normal within 
1 week.
CKs are expressed in cells and released when cell mem-
brane integrity is severely damaged, thereby leading to apop-
tosis or secondary necrosis. It has been noted that peak levels 
of ccCK18 and CK18 were often found within 1 to 3 days after 
administration of chemotherapy.28,31 In fact, during subsequent 
courses, an overall decrease was observed, with the superpo-
sition of peaks for both ccCK18 and CK18.16 Therefore, to 
emphasize the cumulative effect of the antiangiogenic agent in 
combination with chemotherapy and to focus on the predictive 
or monitoring value of CEC and CK level for tumor response 
and potential correlation with survival, we only observed CEC 
and CK levels before and after each cycle instead of shortly 
after treatment in this study. Our data showed that this assay 
protocols would be more feasible and hold clinically efficient 
value.
In conclusion, there seems to be a significant response 
and survival correlation between serum ccCK18 and CEC 
levels in patients with advanced NSCLC treated with pacli-
taxel/carboplatin plus the antiangiogenic agent, endostatin. 
Higher baseline CECs, a greater increase of ccCK18 and a 
reduction of CECs with such treatment seems to represent 
FIGURE 5.  Association between 
CEC reduction and patient sur-
vival in the endostatin group. A, 
ROC analyses revealed best cutoff 
value for prediction of survival of 
0.58/μl, where AUC = 0.759 (95% 
CI = 0.629–0.889). Sensitivity and 
specificity of CEC reduction after 
endostatin therapy calculated using 
ROC analysis for survival were 60% 
and 88%, respectively. B and C, 
When cutoff value of 0.58/μl was 
used, patients with CEC reduction 
less than 0.58/μl (n = 34) had a PFS 
of 5 months and OS of 10.6 months; 
those with CEC reduction more than 
0.58/μl (n = 20) had a PFS of 9.8 
months and an OS of 23.9 months. 
Median survival of patients with 
greater CEC reduction endostatin 
significantly longer than those with 
fewer reduction (p = 0.013 for PFS, 
p = 0.009 for OS). CEC, circulating 
endothelial cells; ROC, receiver oper-
ating characteristic; CI, confidence 
interval; AUC, area under the curve.
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an indirect indicator of tumor cell death and predictor of a 
better response and longer survival. Selecting patients with 
high CECs could prove helpful for decision-making to deter-
mine therapy modality. However, prospective studies will be 
required to confirm the value of these biomarkers during anti-
angiogenic therapy.
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